doi:10.1056/NEJMoa2403347 Data on file
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M
Tirzepatide , available as Mounjaro or Zepbound, is a medication used to manage both type 2 diabetes and obesity
As of early November, when Novo Nordisk and Eli Lilly announced deals with the Trump administration, the starting dose of Zepbound will be available for $299 a month for people buying without using insurance
November 22, 2024: Scientists Ask For More Research About Cancer Risks Associated with Zepbound and GLP-1 Drugs A recent study found that people who took GLP-1 drugs for 1 to 3 years were 58% more likely to develop thyroid cancers
Companies have said they arent getting enough raw materials to make the drugs, and the federal government says companies arent using what they have